8.45

3.17% 0.26

Cervomed Inc (CRVO)

Overview News Price History Discussions Forecast Stock Split

Cervomed Inc stock is traded at $8.45, with a volume of 15,744. It is up +3.17% in the last 24 hours and up +14.11% over the past month. CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Previous Close:

$8.19

Open:

$8.16

24h Volume:

15,744

Relative Volume:

0.18

Market Cap:

$78.19M

Revenue:

Net Income/Loss:

$-6.42M

P/E Ratio:

-1.5086

EPS:

-5.6013

Net Cash Flow:

$-7.45M

1W Performance:

-2.76%

1M Performance:

+14.11%

6M Performance:

+10.89%

1Y Performance:

+337.82%

1-Day Range:

$8.15

$8.45

1-Week Range:

$8.13

$8.93

52-Week Range:

$1.80

$16.94

Cervomed Inc Stock (CRVO) Company Profile

Name

Cervomed Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

(617) 744-4400

Address

20 PARK PLAZA, BOSTON

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

CRVO's Discussions on Twitter

Compare CRVO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRVO Cervomed Inc	8.45	75.78M	0	-6.42M	-7.45M	-5.6013
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Cervomed Inc Stock (CRVO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-13-25	Upgrade	Chardan Capital Markets	Neutral → Buy
Dec-17-24	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-11-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Dec-11-24	Downgrade	Morgan Stanley	Overweight → Underweight
Dec-10-24	Downgrade	D. Boral Capital	Buy → Hold
Dec-06-24	Initiated	ROTH MKM	Buy
Dec-05-24	Initiated	H.C. Wainwright	Buy
Sep-18-24	Initiated	Chardan Capital Markets	Buy
Jul-26-24	Initiated	Morgan Stanley	Overweight
Feb-15-24	Initiated	Canaccord Genuity	Buy
Nov-17-20	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-21-18	Initiated	H.C. Wainwright	Buy

View All

Cervomed Inc Stock (CRVO) Latest News

Dec 11, 2025

New Highs: Can CervoMed Inc. stock rebound after recent weaknessJuly 2025 Gainers & Precise Swing Trade Entry Alerts - moha.gov.vn

Dec 11, 2025

Dec 10, 2025

Pleasing Signs As A Number Of Insiders Buy CervoMed Stock - Yahoo Finance

Dec 10, 2025

Dec 07, 2025

CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Dec 07, 2025

Dec 05, 2025

Published on: 2025-12-06 11:12:10 - moha.gov.vn

Dec 05, 2025

CervoMed Inc Announces New Data from RewinD-LB Trial - TradingView — Track All Markets

Dec 05, 2025

Today's Analyst Rating: CRVO Maintains "Buy" with $31 Price Targ - GuruFocus

Dec 05, 2025

Will CervoMed Inc. (DP8) stock benefit from Fed rate cutsJuly 2025 Intraday Action & Daily Volume Surge Signals - Newser

Dec 05, 2025

What RSI levels show for CervoMed Inc. (DP8) stockPortfolio Gains Report & Technical Confirmation Trade Alerts - Newser

Dec 05, 2025

Why CervoMed Inc. (DP8) stock is a strong analyst pickEarnings Performance Report & Risk Managed Trade Strategies - Newser

Dec 05, 2025

Cervomed (CRVO) Unveils Promising Phase 2b Trial Results for Nef - GuruFocus

Dec 05, 2025

Dec 04, 2025

CervoMed’s DLB drug shows promise in phase 2b trial By Investing.com - Investing.com Nigeria

Dec 04, 2025

CervoMed’s DLB drug shows promise in phase 2b trial - Investing.com

Dec 04, 2025

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - The Manila Times

Dec 04, 2025

CervoMed stock soars after promising dementia drug trial results By Investing.com - Investing.com South Africa

Dec 04, 2025

CervoMed stock soars after promising dementia drug trial results - Investing.com

Dec 04, 2025

CervoMed Inc. Reports Phase 2b RewinD-LB Trial Results for Neflamapimod, Showing Significant Improvements in Dementia with Lewy Bodies Patients - Quiver Quantitative

Dec 04, 2025

CervoMed (NASDAQ: CRVO) Phase 2b shows 75% drop in DLB progression risk, eyes Phase 3 - Stock Titan

Dec 04, 2025

How rising interest rates impact CervoMed Inc. stockPortfolio Value Report & Safe Swing Trade Setups - Newser

Dec 04, 2025

Is CervoMed Inc. stock attractive after correctionJuly 2025 Action & Fast Exit and Entry Strategy Plans - Newser

Dec 04, 2025

Why CervoMed Inc. (DP8) stock stays undervaluedM&A Rumor & Short-Term High Return Strategies - Newser

Dec 04, 2025

Dec 03, 2025

CervoMed's (CRVO) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat

Dec 03, 2025

Neflamapimod reduces key neurodegeneration markers in DLB study By Investing.com - Investing.com Canada

Dec 03, 2025

CervoMed (NASDAQ:CRVO) Receives Buy Rating from D. Boral Capital - Defense World

Dec 03, 2025

Dec 02, 2025

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) - marketscreener.com

Dec 02, 2025

How CervoMed Inc. (DP8) stock gains from tech spending2025 Volume Leaders & Free Real-Time Volume Trigger Notifications - Newser

Dec 02, 2025

Nov 27, 2025

What analyst consensus says on CervoMed Inc. stockRecession Risk & Free Fast Gain Swing Trade Alerts - BỘ NỘI VỤ

Nov 27, 2025

Nov 26, 2025